TABLE 2.

Sequential profiles of CSF from a compromised individual with C. albicans meningitis

DayaAmphotericin B dose (g)bDays of caspofungin useCSF culture for C. albicanscNo. of RBC/mm3 of CSFeNo. of WBC/mm3 of CSFf% S/M/LdCSF glucose level (mg/dl)CSF protein level (mg/dl)
230110,0001,50087/6/718686
330+5,61657684/0/1683106
400+721,15881/19/059117
430.05+5814572/21/77478
570.751201010/70/205749
651.152,0802065/30/565109
711.40+81370/15/156336
781.80+572466/34/07430
1032.901+
1042.952+111470/12/1875
1073.105
10973,8901361/19/184142
1161403572/8/204550
12624040/25/755433
  • a Day 0, the day chemotherapy was started; day 23, the first day a lumbar puncture was performed.

  • b Cumulative dose of parenteral amphotericin B. Total cumulative dose, 3.1 g.

  • c + and −, positive and negative for growth of C. albicans in CSF.

  • d Percentages of segmented neutrophils (S), monocytes (M), and lymphocytes (L), respectively.

  • e RBC, red blood cells.

  • f WBC, white blood cells.